Leiden University Medical Center
lumc.nlLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
328
Active
91
Phase 3
27
Total enrollment
221,936
Pipeline matrix
Showing 40 of 47 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Clindamycin | — | — | — | — | 2 | ||
| Prednisolone | — | — | — | — | 2 | ||
| Cefuroxime | — | — | — | — | — | 1 | |
| Metronidazole | — | — | — | — | — | 1 | |
| Levetiracetam | — | — | — | — | — | 1 | |
| Valproic Acid | — | — | — | — | — | 1 | |
| Rifampicin and levofloxacin | — | — | — | — | — | 1 | |
| Methylprednisolone | — | — | — | — | 3 | ||
| Belimumab | — | — | — | — | — | 1 | |
| Methylprednisolon | — | — | — | — | — | 1 | |
| Olaparib | — | — | — | — | — | 1 | |
| Chemotherapy | — | — | — | — | — | 1 | |
| Durvalumab | — | — | — | — | — | 1 | |
| Medroxyprogesterone Acetate | — | — | — | — | — | 1 | |
| Megestrol Acetate | — | — | — | — | — | 1 | |
| Saline solution | — | — | — | — | — | 1 | |
| Mifepristone 50 mg | — | — | — | — | — | 1 | |
| Wegovy ® | — | — | — | — | — | 1 | |
| Doublet Chemotherapy, Standard Dose | — | — | — | — | — | 1 | |
| Doublet Chemotherapy, Dose-reduced | — | — | — | — | — | 1 | |
| Monotherapy, Standard Dose | — | — | — | — | — | 1 | |
| Monotherapy, Dose-reduced | — | — | — | — | — | 1 | |
| [18F]-FAPI-74 | — | — | — | — | — | 1 | |
| XYWAV | — | — | — | — | — | 1 | |
| Abiraterone acetate | — | — | — | — | — | 1 | |
| Enzalutamide | — | — | — | — | — | 1 | |
| dabrafenib/trametinib | — | — | — | — | — | 1 | |
| Belimumab Prefilled Syringe [Benlysta] | — | — | — | — | — | 1 | |
| Ipilimumab and nivolumab | — | — | — | — | — | 1 | |
| Melphalan chemosaturation via percutaneous hepatic perfusion | — | — | — | — | — | 1 | |
| Low Sodium Oxybate | — | — | — | — | — | 1 | |
| CHMI with 3D7 malaria | — | — | — | — | — | 1 | |
| 2.5 μg InvaplexAR-Detox | — | — | — | — | — | 1 | |
| 10 μg InvaplexAR-Detox | — | — | — | — | — | 1 | |
| 0.1 μg of dmLT | — | — | — | — | — | 1 | |
| Narcan 40 MG/ML Nasal Spray | — | — | — | — | — | 1 | |
| Naloxone Hydrochloride | — | — | — | — | — | 1 | |
| Nalmefene HCl | — | — | — | — | — | 1 | |
| Vancomycin | — | — | — | 3 | |||
| Necator americanus L3 larvae | — | — | — | — | — | 2 |
7 more active programs hidden
Next readouts
- 2024-06-07
- 2025-01-01
- 2025-05
- 2025-07
- 2025-07-01
- 2025-07-01
- 2025-12
- 2026-02
- 2026-03-31
- 2026-05-01
Top conditions
- Cardiovascular Diseases6
- Colorectal Cancer6
- Pulmonary Embolism5
- Myasthenia Gravis5
- Breast Cancer5
- COVID-194
- Rheumatoid Arthritis4
- Schistosomiasis4
Frequently asked questions about Leiden University Medical Center
- How many clinical trials does Leiden University Medical Center have on ClinicalTrials.gov?
- Leiden University Medical Center is listed as the lead sponsor on 328 clinical trials in ClinicalTrials.gov, 91 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Leiden University Medical Center's trials are in Phase 3?
- 27 of Leiden University Medical Center's trials are in Phase 3, spread across 47 active drug programs.
- What therapeutic areas does Leiden University Medical Center focus on?
- Leiden University Medical Center's most-studied conditions on ClinicalTrials.gov are Cardiovascular Diseases, Colorectal Cancer, Pulmonary Embolism, Myasthenia Gravis, Breast Cancer.
- When are Leiden University Medical Center's next clinical trial readouts?
- Leiden University Medical Center has 10 upcoming primary-completion readouts tracked here; the soonest is “Synergetic B-cell Immunomodulation in SLE - 2nd Study.”, expected around 2024-06-07.